Correction: Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study.
Willasch AM, Peters C, Sedláček P, Dalle JH, Kitra-Roussou V, Yesilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AA, Ifversen M, Buechner J, Kriván G, Hamladji RM, Diaz-de-Heredia C, Skorobogatova E, Michel G, Locatelli F, Bertaina A, Veys P, Dupont S, Or R, Güngör T, Aleinikova O, Sufliarska S, Sundin M, Rascon J, Kaare A, Nemet D, Fagioli F, Klingebiel TE, Styczynski J, Bierings M, Nagy K, Abecasis M, Afanasyev B, Ansari M, Vettenranta K, Alseraihy A, Chybicka A, Robinson S, Bertrand Y, Kupesiz A, Ghavamzadeh A, Campos A, Pichler H, Dalissier A, Labopin M, Corbacioglu S, Balduzzi A, Galimard JE, Bader P; EBMT Paediatric Diseases Working Party.
Willasch AM, et al. Among authors: nagy k.
Bone Marrow Transplant. 2021 Oct;56(10):2615. doi: 10.1038/s41409-021-01424-5.
Bone Marrow Transplant. 2021.
PMID: 34413474
Free PMC article.
No abstract available.